HK1116161A1 - Substituted amide derivatives as protein kinase inhibitors - Google Patents

Substituted amide derivatives as protein kinase inhibitors

Info

Publication number
HK1116161A1
HK1116161A1 HK08103876.5A HK08103876A HK1116161A1 HK 1116161 A1 HK1116161 A1 HK 1116161A1 HK 08103876 A HK08103876 A HK 08103876A HK 1116161 A1 HK1116161 A1 HK 1116161A1
Authority
HK
Hong Kong
Prior art keywords
protein kinase
kinase inhibitors
amide derivatives
substituted amide
diseases
Prior art date
Application number
HK08103876.5A
Other languages
English (en)
Inventor
Tae-Seong Kim
David Bauer
Steven Bellon
Alessandro Boezio
Shon Booker
Deborah Choquette
Amico Derin D
Angelo Noel D
Celia Dominguez
Ingrid M Fellows
Julie Germain
Russel Graceffa
Jean-Cristophe Harmange
Satoko Hirai
Daniel La
Matthew Lee
Longbin Liu
Mark H Normal
Michele Pothashman
Philip Roveto
Ning Xi
Aaron C Siegmund
Kevin Yang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1116161A1 publication Critical patent/HK1116161A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
HK08103876.5A 2005-04-27 2008-04-07 Substituted amide derivatives as protein kinase inhibitors HK1116161A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67580505P 2005-04-27 2005-04-27
PCT/US2006/016344 WO2006116713A1 (en) 2005-04-27 2006-04-27 Substituted amide derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1116161A1 true HK1116161A1 (en) 2008-12-19

Family

ID=36617399

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08103876.5A HK1116161A1 (en) 2005-04-27 2008-04-07 Substituted amide derivatives as protein kinase inhibitors

Country Status (34)

Country Link
US (3) US7858623B2 (xx)
EP (1) EP1881976B1 (xx)
JP (1) JP5463033B2 (xx)
KR (1) KR20080004617A (xx)
CN (1) CN101248059A (xx)
AR (1) AR054262A1 (xx)
AU (1) AU2006239216B2 (xx)
BR (1) BRPI0608097A2 (xx)
CA (1) CA2605680C (xx)
CR (1) CR9475A (xx)
CY (1) CY1113324T1 (xx)
DK (1) DK1881976T3 (xx)
EA (1) EA013231B1 (xx)
ES (1) ES2396219T3 (xx)
GT (1) GT200600181A (xx)
HK (1) HK1116161A1 (xx)
HN (1) HN2006016313A (xx)
HR (1) HRP20121069T1 (xx)
IL (1) IL186526A (xx)
JO (1) JO2787B1 (xx)
MX (1) MX2007013216A (xx)
MY (1) MY177111A (xx)
NO (1) NO20076093L (xx)
NZ (1) NZ562595A (xx)
PE (1) PE20061436A1 (xx)
PL (1) PL1881976T3 (xx)
PT (1) PT1881976E (xx)
RS (1) RS52596B (xx)
SI (1) SI1881976T1 (xx)
TW (1) TWI378094B (xx)
UA (1) UA93375C2 (xx)
UY (1) UY29503A1 (xx)
WO (1) WO2006116713A1 (xx)
ZA (1) ZA200708775B (xx)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200536851A (en) * 2004-01-23 2005-11-16 Amgen Inc Compounds and methods of use
ES2438017T3 (es) 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
SI1928454T1 (sl) 2005-05-10 2015-01-30 Intermune, Inc. Piridonski derivati za moduliranje s stresom aktiviranega protein kinaznega sistema
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
CA2608726C (en) 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
AR055206A1 (es) * 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
JP2009529047A (ja) 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
US20090306103A1 (en) * 2006-05-19 2009-12-10 Stephen Boyer Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8778977B2 (en) * 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
EP2089364B1 (en) 2006-11-08 2013-06-12 Bristol-Myers Squibb Company Pyridinone compounds
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
CA2672440A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
AU2007338793B2 (en) 2006-12-20 2012-05-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
RU2495044C2 (ru) * 2007-08-29 2013-10-10 Метилджен Инк. Ингибиторы активности протеинтирозинкиназы
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
AU2008319366B2 (en) * 2007-10-29 2012-03-01 Amgen Inc. Benzomorpholine derivatives and methods of use
TW200924770A (en) 2007-11-06 2009-06-16 Astrazeneca Ab Novel compounds 089
KR101596527B1 (ko) 2008-01-23 2016-02-22 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암에 대한 그의 용도
WO2009094427A1 (en) 2008-01-23 2009-07-30 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
EP2262815A4 (en) 2008-03-05 2012-04-11 Methylgene Inc Inhibitors of protein intolerance activity
CA2723617A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
WO2010039545A2 (en) * 2008-09-23 2010-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
EP2349328A1 (en) * 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
MX2011004018A (es) * 2008-10-14 2011-06-24 Ning Xi Compuestos y metodos de uso.
JP2012511000A (ja) * 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション ホスホイノシチド依存性キナーゼ１（ｐｄｋ１）の阻害剤
US8691866B2 (en) * 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
MX2011011326A (es) * 2009-04-27 2012-02-13 Elan Pharm Inc Antagonistas de piridinona de las integrinas alfa-4.
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
CA2772625A1 (en) * 2009-09-03 2011-03-10 Allergan, Inc. Compounds as tyrosine kinase modulators
WO2011035332A1 (en) * 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
MX2012003644A (es) 2009-10-02 2012-04-30 Astrazeneca Ab Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
WO2011051958A1 (en) 2009-10-30 2011-05-05 E.I. Du Pont De Nemours And Company Fungicidal pyrazolones
WO2011080341A1 (en) 2010-01-04 2011-07-07 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
CN102212062B (zh) * 2010-04-02 2015-04-29 广东东阳光药业有限公司 氨基酯类衍生物及其盐和使用方法
JP2013525286A (ja) * 2010-04-16 2013-06-20 メチルジーン・インコーポレイテッド タンパク質チロシンキナーゼ活性の阻害剤
US8569319B2 (en) 2010-04-29 2013-10-29 Deciphera Pharmaceuticals, LLS Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
EA201690998A1 (ru) 2010-05-17 2017-01-30 Инкозен Терапьютикс Пвт. Лтд. НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
EP2594566A4 (en) * 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
AU2012223639B2 (en) 2011-02-28 2015-03-19 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9283225B2 (en) 2011-08-10 2016-03-15 Merck Patent Gmbh Pyrido-pyrimidine derivatives
WO2013025897A1 (en) 2011-08-16 2013-02-21 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
LT2750768T (lt) 2011-08-30 2019-02-11 Astex Pharmaceuticals, Inc. Decitabino darinio kompozicijos
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
KR20140097402A (ko) * 2011-11-22 2014-08-06 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항증식 활성을 나타내는 피리돈 아미드 및 유사체
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
CN103319468B (zh) * 2012-03-21 2016-07-13 广东东阳光药业有限公司 取代的螺双环化合物及其使用方法和用途
BR112014024251A8 (pt) 2012-03-30 2018-01-23 Rhizen Pharmaceuticals S A novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met
ES2745016T3 (es) 2012-04-13 2020-02-27 Epizyme Inc Bromhidrato de N-((4,6-dimetil-2-oxo-L,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[L,1'-bifenil]-3-carboxamida para su uso en el tratamiento de un trastorno proliferativo celular del sistema hematológico
CN103420986A (zh) * 2012-05-18 2013-12-04 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
US9428460B2 (en) * 2012-06-26 2016-08-30 Bayer Pharma Aktiengesellschaft N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
CN104507930B (zh) * 2012-06-29 2017-10-10 贝达药业股份有限公司 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CN103565653B (zh) * 2012-07-16 2017-01-25 广东东阳光药业有限公司 取代的吡唑酮化合物及其使用方法和用途
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
MX2015001424A (es) * 2012-07-28 2016-03-09 Calitor Sciences Llc Compuestos pirazolona sustituidos y metodos de uso.
TWI565702B (zh) * 2012-08-03 2017-01-11 習寧 取代的吡唑酮化合物及其使用方法
KR101350006B1 (ko) * 2012-09-06 2014-02-13 씨제이제일제당 (주) 피리돈 유도체를 포함하는 단백질 키나제 억제제
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
BR112015008487B1 (pt) 2012-10-15 2022-05-31 Epizyme, Inc Compostos de benzeno substituído, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos para tratar um distúrbio mediado por ezh2
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN105307656B (zh) * 2013-06-06 2019-02-19 利德发现中心有限责任公司 巨噬细胞刺激1受体mst1r的喹啉抑制剂
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
HUE063984T2 (hu) 2013-10-16 2024-02-28 Epizyme Inc Hidroklorid só forma az EZH2 gátlásához
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
CN104974162B (zh) * 2014-04-09 2018-09-14 广东东阳光药业有限公司 双环吡唑酮化合物及其使用方法和用途
WO2015164161A1 (en) * 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
WO2016104617A1 (ja) * 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
RU2750727C9 (ru) * 2015-04-14 2021-08-16 Кьюриент Ко., Лтд. Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
US10577364B2 (en) 2015-07-20 2020-03-03 Betta Pharmaceuticals Co., Ltd Crystalline form of fused pyridine derivative's maleate and uses thereof
CN106632253B (zh) * 2015-11-02 2019-03-22 广东东阳光药业有限公司 一种取代的喹啉化合物的晶型及其药物组合物和用途
CN106632254B (zh) * 2015-11-02 2019-03-01 广东东阳光药业有限公司 一种取代的喹啉化合物的晶型及其药物组合物和用途
US9695150B2 (en) * 2015-11-14 2017-07-04 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
EP3373932B1 (en) * 2015-11-14 2022-03-30 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
CN107286140A (zh) * 2016-04-12 2017-10-24 上海医药工业研究院 取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
WO2017198196A1 (zh) * 2016-05-18 2017-11-23 王子厚 具有抗肿瘤活性的喹啉衍生物
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
CN110383066B (zh) 2016-12-09 2023-03-31 戴纳立制药公司 化合物、组合物和方法
WO2018139527A1 (ja) 2017-01-26 2018-08-02 小野薬品工業株式会社 キノリン誘導体のエタンスルホン酸塩
JP7128204B2 (ja) 2017-04-27 2022-08-30 アストラゼネカ・アクチエボラーグ Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
US11427578B1 (en) 2017-07-18 2022-08-30 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
WO2019048988A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. NOVEL FUNGICIDE HETEROCYCLIC COMPOUNDS
CN111655687A (zh) 2017-09-08 2020-09-11 Pi工业有限公司 新型杀真菌杂环化合物
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
US11447500B2 (en) 2018-03-08 2022-09-20 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
BR112020019191A2 (pt) * 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
CN110372666B (zh) * 2018-04-13 2022-11-08 华东理工大学 喹唑啉类化合物作为egfr三突变抑制剂及其应用
CN110511218A (zh) * 2018-05-21 2019-11-29 中国科学院上海药物研究所 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途
JP7090958B2 (ja) * 2018-06-01 2022-06-27 アドレイ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｃｓｆ１ｒ阻害薬化合物
CN108727386A (zh) * 2018-07-16 2018-11-02 广州医科大学 一种吡唑并嘧啶类化合物及其制备方法和用途
CA3109891A1 (en) * 2018-08-24 2020-02-27 Nanjing Transthera Biosciences Co., Ltd. Quinoline derivative inhibitor: tam, ntrk, and csf1r kinases
WO2020120257A1 (en) 2018-12-11 2020-06-18 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
CA3127791A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
EP4005637A4 (en) * 2019-07-29 2023-07-19 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
MX2022001302A (es) * 2019-08-02 2022-03-02 Amgen Inc Inhibidores de kif18a.
MX2022001467A (es) * 2019-08-08 2022-05-06 B C I Pharma Derivados quinolina como inhibidores de proteína quinasa.
KR20220059386A (ko) 2019-09-06 2022-05-10 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
CA3155924A1 (en) * 2019-09-26 2021-04-01 Exelixis, Inc. PYRIDONE COMPOUNDS AND METHODS OF USE IN MODULATING A PROTEIN KINASE
CN113121429B (zh) * 2020-01-15 2024-04-26 鲁南制药集团股份有限公司 一种c-Met激酶抑制剂及其制备方法和应用
CA3171473A1 (en) * 2020-02-24 2021-09-02 Exelixis, Inc. Compounds and methods of use
CN111440174B (zh) * 2020-04-02 2021-07-09 广州医科大学 一种吡啶酰胺类化合物及其制备方法与应用
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
EP4288437A1 (en) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Map4k1 inhibitors
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
AU2022295990A1 (en) 2021-06-18 2024-01-04 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
TW202315628A (zh) * 2021-06-24 2023-04-16 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物
CN113999205B (zh) * 2021-12-13 2023-09-15 辽宁大学 含三氮唑酮酰胺和咪唑酰胺结构的吡啶类化合物及其应用
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN117362275A (zh) * 2022-06-29 2024-01-09 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
CN116283920B (zh) * 2023-03-31 2024-04-16 贵州医科大学 2,4-二取代吡啶类化合物及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
DE2948434A1 (de) * 1979-12-01 1981-06-11 Hoechst Ag, 6000 Frankfurt 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung
JPS63145272A (ja) 1986-12-09 1988-06-17 Morishita Seiyaku Kk ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体
US4916135A (en) 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
JPH08193070A (ja) * 1995-01-11 1996-07-30 Mitsubishi Chem Corp ２−イミダゾリジノン誘導体及びそれを有効成分とする除草剤、並びにその製造中間体
WO1996023774A1 (fr) 1995-01-31 1996-08-08 Zenyaku Kogyo Kabushiki Kaisha Derives de thioquinoline
GB9505702D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd Fungicidal compounds
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
PL321296A1 (en) 1995-11-14 1997-12-08 Pharmacia & Upjohn Spa Derivatives of aryl and heteroaryl purine
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
ATE345339T1 (de) 1997-02-19 2006-12-15 Berlex Lab N-heterocyclische derivate als nos inhibitoren
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ATE293102T1 (de) 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
MXPA00011773A (es) 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.
MXPA01001893A (es) 1998-08-21 2002-04-24 Parker Hughes Inst Derivados de quinazolina.
ES2208261T3 (es) 1999-01-22 2004-06-16 Kirin Beer Kabushiki Kaisha Derivados de quinolina y derivados de quinazolina.
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
TR200102959T2 (tr) 1999-04-12 2002-04-22 Aventis Pharma Limited İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
SK3832002A3 (en) 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
AU2001250849A1 (en) 2000-03-17 2001-10-03 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
AU2001250850A1 (en) 2000-03-17 2001-10-03 Dupont Pharmaceuticals Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
AU2001268545A1 (en) 2000-06-21 2002-01-08 Alexion Pharmaceuticals, Inc. Libraries displaying human antibody fragments with hybrid complementarity determining regions
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
EP1326859A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives with anti-tumour activity
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1364212B1 (en) 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
EP1392306B1 (en) 2001-06-06 2008-01-16 Aventis Pharma Limited Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
CN100415720C (zh) 2001-06-22 2008-09-03 麒麟医药株式会社 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
WO2002000004A2 (en) 2001-07-05 2002-01-03 Telefonaktiebolaget Lm Ericsson (Publ) Detrimental latch-up avoidans in digital circuits
MXPA04004219A (es) 2001-11-03 2004-09-10 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CN101607958A (zh) 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
EP1548008A4 (en) 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
AU2003285952A1 (en) 2002-10-21 2004-05-13 Irm Llc Pyrrolidones with anti-hiv activity
TW200418466A (en) 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
WO2004078114A2 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
US8013156B2 (en) 2003-03-19 2011-09-06 Exelixis, Inc. Tie-2 modulators and methods of use
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
GB0310401D0 (en) 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
WO2005005389A2 (en) 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
CA2536788A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
EP2612853A1 (en) 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
US7691866B2 (en) 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
TW200536851A (en) 2004-01-23 2005-11-16 Amgen Inc Compounds and methods of use
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7523317B2 (en) 2004-04-29 2009-04-21 International Business Machines Corporation Computer grid access management system
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors

Also Published As

Publication number Publication date
ZA200708775B (en) 2008-06-25
NO20076093L (no) 2008-01-25
IL186526A0 (en) 2008-01-20
HN2006016313A (es) 2010-06-08
EP1881976B1 (en) 2012-10-17
HRP20121069T1 (hr) 2013-01-31
EA200702339A1 (ru) 2008-04-28
US20080312232A1 (en) 2008-12-18
WO2006116713A1 (en) 2006-11-02
GT200600181A (es) 2007-05-08
JO2787B1 (en) 2014-03-15
UY29503A1 (es) 2006-11-30
CR9475A (es) 2008-03-07
US20110118252A1 (en) 2011-05-19
AR054262A1 (es) 2007-06-13
JP2008539275A (ja) 2008-11-13
US7858623B2 (en) 2010-12-28
US8088794B2 (en) 2012-01-03
AU2006239216B2 (en) 2012-11-29
US8685983B2 (en) 2014-04-01
IL186526A (en) 2012-10-31
MY177111A (en) 2020-09-07
NZ562595A (en) 2011-02-25
JP5463033B2 (ja) 2014-04-09
MX2007013216A (es) 2007-12-12
CN101248059A (zh) 2008-08-20
SI1881976T1 (sl) 2013-01-31
PL1881976T3 (pl) 2013-03-29
KR20080004617A (ko) 2008-01-09
PE20061436A1 (es) 2007-02-08
TWI378094B (en) 2012-12-01
AU2006239216A1 (en) 2006-11-02
CY1113324T1 (el) 2016-06-22
UA93375C2 (ru) 2011-02-10
EA013231B1 (ru) 2010-04-30
US20120070413A1 (en) 2012-03-22
DK1881976T3 (da) 2013-02-04
BRPI0608097A2 (pt) 2009-11-10
PT1881976E (pt) 2012-11-21
CA2605680A1 (en) 2006-11-02
TW200716596A (en) 2007-05-01
EP1881976A1 (en) 2008-01-30
ES2396219T3 (es) 2013-02-20
CA2605680C (en) 2012-10-16
RS52596B (en) 2013-04-30

Similar Documents

Publication Publication Date Title
HK1116161A1 (en) Substituted amide derivatives as protein kinase inhibitors
MY167135A (en) Fused heterocyclic derivatives and methods of use
MY159615A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
TNSN06228A1 (en) Compounds and methods of use
ATE404552T1 (de) Substituierte isochinolinderivate und anwendungsverfahren
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
WO2008079291A3 (en) Substituted heterocycles and methods of use
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
WO2004005279A3 (en) Substituted anthranilic amide derivatives and methods of use
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
WO2004007481A3 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders
RS60503A (xx) Derivati supstituisanih alkilamina i postupci za njihovu upotrebu
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren
WO2006041888A3 (en) Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents
MX2010004620A (es) Derivados de benzomorfolina y metodos de uso.
TN2010000318A1 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170427